Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

5.9K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.9K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

5.0K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Cancer Therapies02:49

Cancer Therapies

8.0K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Health system learning enables generalist neuroimaging models.

Nature medicine·2026
Same author

Mechanisms of caries induced by sugars: a narratives review from microbial metabolism to oral ecological imbalance and public health strategies for caries prevention.

Frontiers in cellular and infection microbiology·2026
Same author

Radiation induces an EGFR-dependent lactate-epigenetic program underlying synergy with EGFR inhibition.

Cellular oncology (Dordrecht, Netherlands)·2026
Same author

Clinical heterogeneity in congenital factor XII deficiency: Coexisting risk factors in thrombotic and bleeding events.

British journal of haematology·2026
Same author

Hemodynamics Beyond Ischemic Zone Underlies Early Neurological Deterioration in Minor Stroke with Large Vessel Occlusion.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
Same author

Cooperating under social anxiety: EEG hyperscanning reveals heightened interbrain synchrony and ERP responses in socially anxious adolescents.

Acta psychologica·2026

Related Experiment Video

Updated: Sep 13, 2025

Radiosensitivity of Cancer Stem Cells in Lung Cancer Cell Lines
09:45

Radiosensitivity of Cancer Stem Cells in Lung Cancer Cell Lines

Published on: August 21, 2019

7.2K

Mechanisms Underlying Radioresistance and Reversal Strategies in Non-Small Cell Lung Cancer.

Chenhui Zhao1, Shilan Luo1, Qing Shao1

  • 1Department of Radiation Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200000, China.

International Journal of Molecular Sciences
|July 29, 2025
PubMed
Summary

This review explores radioresistance in non-small cell lung cancer (NSCLC) treated with radiotherapy (RT). Understanding mechanisms like DNA repair and tumor microenvironment is key to developing new strategies and biomarkers to improve patient outcomes.

Keywords:
non-small cell lung cancerpotential biomarkersradioresistance mechanismsradiotherapyreversal strategies

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.9K
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.0K

Related Experiment Videos

Last Updated: Sep 13, 2025

Radiosensitivity of Cancer Stem Cells in Lung Cancer Cell Lines
09:45

Radiosensitivity of Cancer Stem Cells in Lung Cancer Cell Lines

Published on: August 21, 2019

7.2K
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.9K
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.0K

Area of Science:

  • Oncology
  • Radiation Oncology
  • Cancer Biology

Background:

  • Radiotherapy (RT) is a cornerstone in non-small cell lung cancer (NSCLC) treatment.
  • Tumor radioresistance significantly limits therapeutic efficacy in a subset of NSCLC patients.
  • A comprehensive understanding of radioresistance mechanisms is crucial for improving RT outcomes.

Purpose of the Study:

  • To review and delineate the multifaceted mechanisms underlying radioresistance in NSCLC.
  • To explore novel therapeutic strategies aimed at overcoming NSCLC radioresistance.
  • To provide an overview of potential biomarkers for predicting RT response in NSCLC.

Main Methods:

  • Literature review and synthesis of current research on NSCLC radioresistance.
  • Identification and categorization of key molecular and cellular mechanisms contributing to radioresistance.
  • Exploration of emerging therapeutic approaches and predictive biomarkers.

Main Results:

  • Radioresistance in NSCLC involves complex mechanisms including DNA repair, cell cycle, cancer stem cells (CSCs), epithelial-mesenchymal transition (EMT), hypoxia, and the tumor microenvironment (TME).
  • Other contributing factors include dysregulated cell death, metabolic reprogramming, exosome signaling, genetic mutations, signaling pathways, and epigenetic modifications.
  • Novel strategies and potential biomarkers for enhancing radiosensitivity and predicting RT response were identified.

Conclusions:

  • Addressing the diverse mechanisms of radioresistance is essential for improving radiotherapy efficacy in NSCLC.
  • Combination therapies targeting identified resistance pathways hold promise for better patient outcomes.
  • Biomarker discovery is critical for personalized RT approaches in NSCLC management.